enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. CARVYKTI® Significantly Improved Minimal Residual Disease ...

   lite.aol.com/tech/story/0022/20241209/9316602.htm

   Data from CARTITUDE-4 supported the U.S. Food and Drug Administration (FDA) and European Commission (EC) approval of CARVYKTI ® earlier this year for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a PI, and IMiD, and are refractory to lenalidomide. 1 ...

3. Chemotherapy regimen - Wikipedia

   en.wikipedia.org/wiki/Chemotherapy_regimen

   multiple myeloma, AL amyloidosis DA or DAC: daunorubicin x 3 days plus ara-C x 7 days, a variant of 7+3 regimen Acute myeloid leukemia, excluding acute promyelocytic leukemia: DAT: daunorubicin, cytarabine (ara-C), tioguanine: Acute myeloid leukemia: DCEP dexamethasone, cyclophosphamide, etoposide, platinum agent

4. Multiple myeloma - Wikipedia

   en.wikipedia.org/wiki/Multiple_myeloma

   MGUS is a relatively stable condition afflicting 3% of people aged 50 and 5% of people aged 70; it progresses to multiple myeloma at a rate of 0.5–1% cases per year; smoldering multiple myeloma does so at a rate of 10% per year for the first 5 years, but then falls off sharply to 3% per year for the next 5 years and thereafter to 1% per year.

5. Sofosbuvir/velpatasvir - Wikipedia

   en.wikipedia.org/wiki/Sofosbuvir/velpatasvir

   Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]

6. Here's What Hepatitis C Actually Is—and How You Get It - AOL

   www.aol.com/lifestyle/heres-hepatitis-c-actually...

   In fact, the rate of new hepatitis C cases more than quadrupled over the last decade, according to a study conducted by the Centers for Disease Control and Prevention (CDC). Dr. Dr.

7. Hep C Drugmakers' Best Outcome - AOL

   www.aol.com/news/2012-03-16-hep-c-drugmakers...

   Treating hepatitis C is a losing proposition. Unlike treatments for chronic diseases -- high blood pressure or diabetes, for instance -- if a hepatitis C drug does its job, the patient is cured.